Search

COVID-19 Expert opinions

Expert opinions for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in many patients with hematologic diseases.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

EHA-SLCH Hematology Tutorial on Hematological Disorders

Date: March 18-19, 2022

Format: Hybrid

EHA and the Sri Lanka College of Haematologists (SLCH) are happy to have successfully organized the EHA-SLCH Hematology Tutorial on Hematological Disorders on March 18 and 19, 2022.

Read more

The ‘i4MDS’ consortium looks to the future at its second general meeting

Feb 29 2024 Posted in Meeting reports Tagged i4MDS

The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more

Lymphoid malignancies dissected in Warsaw

The EHA–PTHiT Tutorial on Lymphoid Malignancies was held on March 17-18, 2017 in Warsaw, Poland. 96% of meeting attendees were satisfied with the tutorial saying that their expectations are met.

Read more

3rd Highlights of Past EHA (HOPE) in 2020 focused on Latin America a success!

November 13, 2020

Meeting Chairs:

Prof J Gribben (European Hematology Association)
Prof G Stemmelin (Argentinian Society of Hematology)

On November 13, EHA and the Argentinian Society of Hematology (SAH) kicked-off the second HOPE Latin America meeting in a virtual format.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more